Skip to main content
. 2019 Aug 29;8(9):1340. doi: 10.3390/jcm8091340

Table 2.

Published studies on lupus podocytopathy.

Author, Year N. pat. Inclusion Criteria Clinical Presentation Histology Prognosis
Light Microscopy Ig Deposits FPE Response Relapse and Hist. Trans.
Hertig, 2002 [100] n = 11

  1. Lupus dg *

  2. NS

  3. MCD/FSGS

 Female 27 years
NS: 100%Hu: 30%AKI: 55%
Time onset LES/NS: 5 months		 Ms proliferation: 0%
MCD: 30%
FSGS: 70%		 Ms deposit: 30% - CR: 70% Relapse: 30%
Hist. Trans.: -
Kraft, 2005 [102] n = 18

  1. Lupus dg *

  2. MCD/FSGS Class I/II appearance

 Female 30 years
NS: 45%Hu: 60%AKI: 20%
Time onset LES/NS: 1 month (in NS range)		 Ms proliferation: 75%
MCD: 15%
FSGS: 45%		 Ms deposit: 75% FPE: >80% in 90% of NS CR/PR: 75% Relapse: -
Hu, 2016 [103] n = 50

  1. Lupus dg *

  2. NS

  3. MCD/Class I/II or FSGS

  4. with FPE > 50%

 Female 30 years
NS: 100%Hu: 20–30%AKI: Class I/II appearance: 20%; FSGS 70%
Time onset LES/NS: 5 months		 Ms proliferation: 74%
MCD: 26%
FSGS: 18%		 Ms deposit: 90% FPE: >70% in 90% of patients CR: 75%PR: 20% Relapse: 50%
Hist. Trans.: 40%
Wang, 2017 [104] n = 31

  1. Lupus dg *

  2. NS

  3. Class II appearance

  4. FPE > 50%

 Female 30 years
NS: 100% Hu: 20%AKI: 30%
Time onset LES/NS: 6 months		 Ms proliferation: 100% Ms deposit: 100% FPE: >70% in 75% of patients CR: 85%PR: 10% Relapse: 50%
Hist. Trans: 60%

* According to the American Rheumatologic Association criteria. N. pat. : Number of patients. MCD: minimal change disease; FSGS: focal segmental glomerulosclerosis; Ig: immunoglobulin; NS: nephrotic syndrome; Hu: hematuria; AKI: acute kidney injury; Ms: mesangial; FPE: foot process effacement; CR/PR: complete/partial remission; Hist. Trans: histological transition.